Tandem Diabetes Care price to free cash flow TNDM

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 240×; Apr 2025
7-year median: 98.9×
7-year range: 41.5× to 295×
Peer median: 17.6×

Tandem Diabetes Care's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Apr 2025, at 240×.

On the days it had one over the last 7 years, its median was 98.9×, from 41.5× in Jul 2022 to 295× in Feb 2025.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	240×	224×	295×
2024	n/m a value too high to mean anything
2023	156×	85.9×	166×
2022	96.1×	41.5×	96.1×
2021	101×	87.2×	137×
2020	198×	133×	227×
2019	155×	148×	178×

Against its peers

Companies in Medical - Instruments & Supplies nearest Tandem Diabetes Care's size, closest first, today.

Company	Price to free cash flow
TNDMTandem Diabetes Care	n/m
BVSBioventus	13.3×
CDRECadre	16.4×
STAAStaar Surgical	n/m
IRMDIradimed	43.7×
EYENational Vision	30.1×
LMATLemaitre Vascular	26.2×
INSPInspire Medical Systems	17.6×
MOVMovado	9.8×
UFPTUFP Technologies	n/m
MDXGMimedx	n/m
Peer median	17.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Tandem Diabetes Care

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.